{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:15:39Z","timestamp":1789514139278,"version":"build-2803163510"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":2251,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>\n                    <jats:list list-type=\"explicit-label\">\n                      <jats:list-item>\n                        <jats:p>Contractility studies were undertaken to determine the nature of the receptors mediating responses to tachykinins in uteri of oestrogen\u2010treated mice.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          In the presence of thiorphan, (3 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ), captopril (10 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ) and bestatin (10 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ), substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) produced concentration\u2010related contractions of uterine preparations. The order of potency was SP NKA&gt;NKB.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          Neither atropine (0.1 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ) nor l\u2010NOLA (100 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ), nor indomethacin (10 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ) alone or in combination with either ranitidine (10 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ) or mepyramine (10 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ), affected responses to SP. These findings indicate that SP actions are not mediated or modulated through the release of acetylcholine, nitric oxide, prostanoids or histamine.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          In the presence of peptidase inhibitors, the tachykinin NK\n                          <jats:sub>1<\/jats:sub>\n                          receptor\u2010selective agonist [Sar\n                          <jats:sup>9<\/jats:sup>\n                          Met(O\n                          <jats:sub>2<\/jats:sub>\n                          )\n                          <jats:sup>11<\/jats:sup>\n                          ]SP, produced a concentration\u2010dependent contractile effect. The tachykinin NK\n                          <jats:sub>2<\/jats:sub>\n                          and NK\n                          <jats:sub>3<\/jats:sub>\n                          receptor\u2010selective agonists [Lys\n                          <jats:sup>5<\/jats:sup>\n                          MeLeu\n                          <jats:sup>9<\/jats:sup>\n                          Nle\n                          <jats:sup>10<\/jats:sup>\n                          ]NKA(4\u201010) and [MePhe\n                          <jats:sup>7<\/jats:sup>\n                          ]NKB were relatively inactive. The potencies of SP analogues in which Glu replaced Gln\n                          <jats:sup>5<\/jats:sup>\n                          and\/or Gln\n                          <jats:sup>6<\/jats:sup>\n                          were similar to that of SP.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          The tachykinin NK\n                          <jats:sub>1<\/jats:sub>\n                          receptor\u2010selective antagonist, SR140333 (10 n\n                          <jats:sc>M<\/jats:sc>\n                          ), alone or combined with the tachykinin NK\n                          <jats:sub>2<\/jats:sub>\n                          receptor\u2010selective antagonist, SR48968 (10 n\n                          <jats:sc>M<\/jats:sc>\n                          ), shifted log concentration curves to SP, NKA and NKB to the right. SR140333 (10 n\n                          <jats:sc>M<\/jats:sc>\n                          ) reduced the effect of [Sar\n                          <jats:sup>9<\/jats:sup>\n                          Met(O\n                          <jats:sub>2<\/jats:sub>\n                          )\n                          <jats:sup>11<\/jats:sup>\n                          ]SP. SR48968 did not affect responses to SP or [Sar\n                          <jats:sup>9<\/jats:sup>\n                          Met(O\n                          <jats:sub>2<\/jats:sub>\n                          )\n                          <jats:sup>11<\/jats:sup>\n                          ]SP, but reduced the effect of higher concentrations of NKA and shifted the log concentration\u2010response curve to NKB to the right. The tachykinin NK\n                          <jats:sub>3<\/jats:sub>\n                          receptor\u2010selective antagonist, SR 142801 (0.3 \u03bc\n                          <jats:sc>M<\/jats:sc>\n                          ), had little effect on responses to SP and NKB.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          We conclude that the tachykinin NK\n                          <jats:sub>1<\/jats:sub>\n                          receptor mediates contractile effects of SP, NKA and NKB and [Sar\n                          <jats:sup>9<\/jats:sup>\n                          Met(O\n                          <jats:sub>2<\/jats:sub>\n                          )\n                          <jats:sup>11<\/jats:sup>\n                          ]SP in myometrium from the oestrogen\u2010primed mouse. The tachykinin NK\n                          <jats:sub>2<\/jats:sub>\n                          receptor may also participate in the responses to NKA and NKB.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>British Journal of Pharmacology<\/jats:italic>\n                    (2002)\n                    <jats:bold>137<\/jats:bold>\n                    , 1247\u20131254. doi:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0704996\">10.1038\/sj.bjp.0704996<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1038\/sj.bjp.0704996","type":"journal-article","created":{"date-parts":[[2002,12,4]],"date-time":"2002-12-04T13:22:03Z","timestamp":1039008123000},"page":"1247-1254","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Functional characterization of tachykinin NK\n                    <sub>1<\/sub>\n                    receptors in the mouse uterus"],"prefix":"10.1111","volume":"137","author":[{"given":"Eva","family":"Patak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn N","family":"Pennefather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot E","family":"Story","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)80041-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00226501"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod53.4.814"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90726-7"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00848-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod65.2.538"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(91)90137-8"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(87)90088-6"},{"key":"e_1_2_7_10_1","first-page":"L27","article-title":"SR 142801, the first potent non\u2010peptide antagonist of the tachykinin NK3 receptor","volume":"56","author":"EMONDS\u2010ALT X.","year":"1995","journal-title":"Life Sci."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90027-F"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90352-P"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01229-6"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0143-4179(98)90063-4"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.1999.03119.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(93)90098-S"},{"key":"e_1_2_7_17_1","first-page":"176","article-title":"Effects of tachykinins on contractile activity of the oestrogen\u2010primed mouse uterus","volume":"5","author":"FLEMING A.J.","year":"1998","journal-title":"Proc. ASCEPT"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(87)90117-3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02133783"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01003727"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02252943"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.8755-8920.2001.450506.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00500282"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(94)00292-U"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(88)90002-X"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)85416-7"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701613"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1997.tb00197.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1999.tb00073.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00359-3"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.62041399.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/35015579"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00090-8"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2000.03362.x"},{"key":"e_1_2_7_35_1","first-page":"65","article-title":"Tachykinins acting at NK2 receptors cause contraction of human uterine tissue from non\u2010pregnant women","volume":"7","author":"PATAK E.N.","year":"2000","journal-title":"Proc. ASCEPT"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/6.6.549"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(93)90025-C"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01186-4"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)00150-7"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90359-3"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703410"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00489542"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0143-4179(97)90055-X"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00298-7"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704996","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0704996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:54:12Z","timestamp":1695887652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0704996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1038\/sj.bjp.0704996"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0704996","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}